哮喘临床分型和个体化治疗的转化应用  

The development of clinical type and personalized therapy for asthma:from bench to bed

作　　者：陈智鸿[1] 苏孝琼 王向东[2] 

机构地区：[1]复旦大学附属中山医院呼吸科,上海200032 [2]复旦大学附属中山医院实验研究中心,上海200032

出　　处：《转化医学研究（电子版）》2014年第4期95-104,共10页Translational Medicine Research(Electronic Edition)

基　　金：国家自然科学基金(81270078;81470211);上海市重点学科建设(B115)资助

摘　　要：随着对哮喘致病机制的深入认识,近年来提出按照临床、病理、分子生物学特征对哮喘进行更精细划分。当哮喘按照"内型"理论研发的靶向药物在特定类型哮喘患者中取得了很好的疗效后,"同一疗法适合所有患者"的治疗理念正受到挑战。同时也预示了传统的哮喘非特异性治疗(如糖皮质激素、茶碱等为主的基础治疗)模式,将转向以靶向为主的特异性治疗(如抗IgE,抗IL-5单抗治疗等)模式。新疗法的研制成功将开辟哮喘治疗的崭新领域。With deep understanding of pathogenesis in asthma,this disorder with vast heterogeneity should be redefined by clinical,pathologic and molecular biological characteristics.As the target-therapy has succeeded in specific subgroup of asthmatics according to ＂endotype＂ theory, ＂one size fits all＂ approach is facing major challenges.It implies traditional non-specific asthma treatment such as corticosteroid,theophylline will turn to target-therapy dominated specific treatment such as antiIgE,anti-IL-5 antibody et aL These new therapies will open a brand-new field for asthma treatment.

关 键 词：哮喘 内型 个体化治疗 

分 类 号：R562.25[医药卫生—呼吸系统]